



1. Introduction  
Various national clinical guidelines recommend cognitive behavioural therapy (CBT) 
for patients experiencing psychosis (e.g. Australia & New Zealand, Galletly et al. 2016; 
Canada, Norman et al. 2017; United Kingdom, NICE 2014). In CBT, the therapist and service 
user collaboratively work towards mutually defined goals, and explore how individuals’ 
thoughts, feelings and behaviours might maintain their difficulties over time (Morrison et 
al., 2004). Meta-analyses have shown modest to small effects when exploring whether CBT 
is effective for treating psychotic disorders (Jauhar et al., 2014; Pilling et al., 2002; Turner et 
al., 2013; Wykes et al., 2008; Zimmermann et al., 2005). It is possible that there exist 
subgroups of patients, with certain symptom profiles, where CBT is less effective (Pickles & 
Croudace, 2010). This might include patients with high levels of hopelessness, low insight, or 
more severe psychosis (Birchwood et al., 2018; Brabban et al., 2009; Garety et al., 1997). It 
might also be true of individuals experiencing thought disorder.   
Thought disorder refers to disorganised thinking, evidenced by disorganised speech. 
Originally described as a ‘loosening of associations’ (Bleuler, 1911), it likely includes a variety 
of cognitive and linguistic difficulties, such as tangentially, illogicality, thought block, 
concrete thinking and pressurised communication. Thought disorder is common in 
psychosis, with estimates of prevalence ranging from 5% to 91% depending on how it is 
defined and assessed (Roche et al., 2015). It is associated with adverse outcomes, including 
worse illness course (Wilcox et al., 2012), impaired functioning (Bowie & Harvie, 2008), and 
poor quality of life (Tan et al., 2014). Thought disorder can present as stable over time, but 
typically increases during periods of acute psychosis (Docherty et al., 2003).  
There exists scepticism around offering CBT to individuals experiencing thought 
disorder, likely due to the view that communication difficulties will impede learning through 
verbal dialog. In support of this view, there is evidence that higher levels of thought dsiorder 
are associated with lower clinician ratings of therapeutic alliance (Cavelti et al., 2016; 
Lysaker et al., 2011), which is a crucial factor in the efficacy of CBT and other therapies 
(Goldsmith et al., 2015). However, researchers have seldom investigated or verified the 
direct effect of thought disorder on the efficacy of CBT for psychosis. Thomas and collegaues 




auditory hallucinations under CBT, but the study was small, uncontrolled, and with no long-
term follow up.   
Further research based upon controlled trials would allow for a more definitive 
answer on whether CBT is a viable treatment option in clients experiencing thought 
disorder.  This is turn could lead to better allocation and prioritisation of treatment. This 
article contains reanalysis of data from two randomised controlled trials evaluating CBT for 
psychosis. The aim was to investigate whether thought disorder interfered with the 
effectiveness of CBT for key therapeutic outcomes, namely hallucinations and delusions. We 
hypothesised that thought disorder would reduce the effectiveness of CBT for psychosis 
compared to treatment as usual treatment as usual and supportive counselling.  
 
2. Materials and methods 
2.1. Participants 
We used data from two randomized controlled trials of CBT conducted in the UK: The 
Study of Cognitive Reality Alignment Therapy in Early Schizophrenia (SOCRATES; Lewis et al., 
2002, Tarrier et al., 2004), and The Assessment of Cognitive Therapy Instead of Neuroleptics 
(ACTION; Morrison et al., 2014). We chose these because they were both controlled trials 
comparing CBT with treatment as usual, using the same measures of symptoms and thought 
disorder, with long-term follow-ups. Many trials of CBT for psychosis exclude patients with 
high levels of thought disorder precluding their use for such analysis.  
SOCRATES was a multicentre prospective trial of CBT or supportive counselling 
compared to treatment as usual. Participants were 308 patients diagnosed with 
schizophrenia-spectrum disorders, who had been hospitalised for a recent, acute, first or 
second psychotic episode. Patients were assessed at study baseline before randomization to 
treatment and then at 1.5, 3, 9 and 18 months. Tarrier et al. (2004) provide full details of the 
study and outcomes at the 18-month follow up point.  
ACTION was a multicentre randomized controlled trial of CBT versus treatment as usual 




entry criteria for an early intervention for psychosis service. All participants had chosen not 
to take antipsychotic drugs for at least 6 months prior to the study. Assessments were made 
at pre-randomisation baseline, then at 3, 6, 9, 12, 15 and 18 months. Morrison et al. (2014) 
provide further details. 
2.2. Measures 
The outcome measures were the frequency and distress scores for the paranoid 
delusions and auditory hallucinations scales of PSYRATS, a well-validated assessment tool 
for common positive psychotic symptoms (Haddock et al., 1999). Scores on both scales 
ranged from 0 (symptom absent/no distress) to 4 (continuous symptom 
experience/maximum distress). A score of 0 on the frequency scale necessarily resulted in a 
missing response for the associated distress scale. 
The key predictor variable was thought disorder, which was based on clinician / 
researcher ratings using the Positive And Negative Syndrome Scale (PANSS; Kay et al., 1987). 
We operationalized thought disorder scores based upon psychometric analysis in Drake et 
al. (2003), which comprised the average of responses to the following PANSS items: P2 
(conceptual disorganization), P4 (excitement), N5 (Difficulty in abstract thinking), and G11 
(poor attention). These items loaded consistently onto the same principal component at 
each stage of follow-up of the SOCRATES study and constituted a principal component of 
the change scores across follow-up (Drake et al, 2003). Scores could range from 1 (absent) 
to 7 (extreme). Chronbach’s alphas were above 0.7 in all waves.   
The other predictor variables were as follows:  
Treatment: Participants who received CBT were compared with those allocated to 
treatment as usual in both SOCRATES and ACTION datasets, and with those allocated to 
supportive counselling in SOCRATES.  
Data collection site: Participants recruited in Manchester were compared to those 
recruited in other centres; with those from Nottingham and from Liverpool in the SOCRATES 




Demographics: Variables for male sex and non-white ethnicity were compared with 
females and white ethnicity, respectively; we also controlled for age in years at baseline.   
Duration of untreated psychosis: The natural logarithm of the Duration (in months) of 
Untreated Psychosis was included due to the possible influence on long-term symptomatic 
outcomes (Marshall et al., 2005)  
First episode: For the SOCRATES data only, we compared patients who had experienced 
more than one psychotic episode with those experiencing their first episode (first episode 
status was not available in the ACTION dataset). 
We also included the interaction between treatment and thought disorder, to capture 
the moderating effect of thought disorder on treatment efficacy. All continuous predictors 
(thought disorder, baseline symptoms, age and log duration of untreated psychosis) were 
mean-centred.  Age, sex and phase of illness are all well replicated predictors of outcome in 
models adjusting for baseline symptom severity. Ethnicity is less clear as an independent 
factor, but along with other demographic variables acted as a proxy for important cultural 
and personal variables that had the possibility of affecting the therapy process (e.g. fluency 
in English, conceptual model of psychosis).  
 
2.3. Analysis 
2.3.1. Statistical Models  
We modelled the development of the symptom outcomes using latent growth curve 
models (McArdle & Epstein, 1987). Separately for each symptom, we fitted parallel growth 
curves for the longitudinal development of frequency and distress, with latent intercepts 
and slopes for each. The latent intercept represented a participant’s frequency or distress 
score at the first post-randomization assessment and the latent slope represented the linear 
change in symptoms from then until the final assessment 18 months later. The latent 
intercepts and slopes were regressed upon two nested sets of predictors, set 1 and set 2. 
Set 1 comprised the symptom score at baseline (i.e. pre-randomisation), age, log duration of 
untreated psychosis, and dummy variables for treatment, site, sex, non-white ethnicity and 




encompassed the first set plus thought disorder at baseline and the interaction between 
thought disorder and treatment. The second set therefore represented the additional effect 
that thought disorder had on the treatment-specific development of symptoms over time. 
 
--- Figure 1 about here --- 
 
Figure 1 shows a path diagram for the general model structure. The boxes to the left 
represent the observed symptom frequency scores at the post-randomisation assessments 
(four assessments are shown here, corresponding to the SOCRATES study; in the ACTION 
study there were six). To the right the boxes represent symptom distress scores, which were 
observed only for participants with non-zero symptom frequency. The circles represent the 
latent intercept and slope factors, which are indicated by the observed frequency and 
distress scores. Correlations among the latent growth factors are not shown to reduce 
clutter. The loadings for the intercept factors were fixed to one and each loading for the 
slope factor was fixed to its corresponding number of months since the first post-baseline 
assessment. Completing the picture are the boxes in the centre, representing the predictors 
of the latent growth intercepts and slopes; the boxes with faint outlines are the predictors 
in set 1, with bold outlines the predictors in set 2.  
2.3.2. Estimation 
The distributions of the delusions scores were positively skewed so we estimated the 
models using a robust maximum likelihood estimator that compensates for non-normality 
and heteroscedasticity (the Huber-White ‘sandwich’ estimator; White, 1980). The 
hallucination scores were severely non-normal because many participants had no 
hallucinations, so following Lewis et al. (2002) we dichotomized the hallucination outcomes 
into participants reporting no vs. any frequency or distress; we then modelled them as 
binary outcomes.  
We fitted the models initially as Generalized Structural Equation Models (GSEMs) in 




measures and hallucinations as binary measures modelled using a logistic link function. 
Model estimation was by Monte Carlo numerical integration with 5000 integration points 
(necessary because of the severe computational burden of fitting the logistic models with 
four latent dimensions; see Asparouhov & Muthen, 2012). Because of the complexity of the 
models and the small sample size of the ACTION data, we also respecified1 and fitted the 
models as hierarchical generalized linear mixed effects models (i.e. generalized multilevel 
models; GMLMs) using the mixed (for delusions) and melogit (for hallucinations) 
procedures in Stata 14 (StataCorp, 2015). These were fitted as a robustness check and 
sensitivity analysis on the GSEM results. 
 
2.3.3. Inference 
We compared the set 1 and set 2 models using likelihood ratio tests for both the GSEM 
and GMLM models. Outcomes showing significant differences using both modelling 
approaches were then evaluated in detail.  This was an exploratory analysis looking for 
evidence of potential harm or reduced effectiveness of CBT when coupled with thought 
disorder. The risks associated with a type II error were therefore higher than usual, and to 
reflect this we set our alpha value for statistical significance at 0.1.  
 
3. Results 
Table 1 shows the SOCRATES participants were predominately white males experiencing 
their first psychotic episode. Average symptom levels were quite high at baseline, as would 
be expected for this acute sample. The ACTION participants were more evenly split by sex, 
with longer average duration of untreated psychosis, but generally lower symptom 
frequency scores. Our sample sizes were slightly smaller than the number of recruited 
participants because of missing covariate data. 
                                                          
1 SEMs and multilevel models (MLMs) are distinct but comparable approaches to fitting growth curve models 
(Chou, Bentler, & Pentz, 1998); using both gave us a useful sensitivity analysis for the stability of our results to 





In estimating the GSEM models, the residual variances for the delusion distress score 
at 18 months and the variance of the delusion distress latent slope factor were both very 
small and inadmissible (negative). Following accepted practice we fixed them to zero to 
produce an acceptable model (Chen et al., 2001). For the GMLM models, the full model for 
hallucination responses was too demanding for our computing facilities to estimate, even 
using the Laplace approximation to the standard Gauss-Hermite adaptive quadrature; we 
therefore divided it into separate models for the hallucination frequency and distress. Table 
2 shows the likelihood ratio tests comparing the models with set 1 and set 2 predictors. 
 
--- Table 1 about here --- 
 
--- Table 2 about here --- 
The set 2 models were a significant improvement for both the GSEM and GMLM 
approaches for the SOCRATES delusions outcomes. The SOCRATES Hallucination GSEM 
model difference was also significant, but this difference was reflected only in the distress 
outcomes for the GMLM. Neither of the ACTION symptom outcomes had significant 
differences between sets 1 and 2 for both the GSEM and GMLM approaches. We therefore 
went on to examine the GSEM results for the set 2 models for SOCRATES delusion frequency 
and distress, and hallucination distress.  
 
--- Table 3 about here --- 
 
Table 3 shows the estimates for the set 2 predictors of the latent growth factors for 
these models. The most clear and consistent finding was that there were no significant 
differences in delusion frequency or distress between CBT and treatment as usual, either at 
the 1.5 month post-randomisation point (i.e. on the growth intercept) or in the subsequent 
linear change up to the 18 month point (i.e. on the growth slope), regardless of the level of 




There were significant differences between CBT and supportive counselling in 
delusion frequency, which are illustrated in Figure 2. At the 1.5 month point delusion 
frequency was much higher with supportive counselling compared to CBT, but this 
difference was reduced somewhat with higher levels of thought disorder. The subsequent 
rate of reduction in delusion frequency to the 18 month point was more rapid for 
supportive counselling compared to CBT, but this difference in the rate of improvement was 
slower the higher the thought disorder.  
The size of the effects of thought disorder on delusions were small for both the 
intercept and slope, with an R-square change in the latent growth factors from set 1 to set 2 
of 4.2% and 7.2% respectively.  
 
 
--- Figure 2 about here --- 
 
The lower panel in Table 3 shows the results for hallucination distress. There were 
again no significant differences between CBT and treatment as usual. There were significant 
effects of CBT vs. supportive counselling at the 1.5 month point, but no significant effects 
for subsequent change till 18 months. At 1.5 months, participants allocated to supportive 
counselling had significantly higher probability of hallucinations (the very high logit 
coefficient of nearly 13 corresponding to a near-certainty of reporting hallucinations), but 
the difference with CBT was smaller with increasing thought disorder. Figure 3 illustrates 
these effects, showing that hallucinations were rare for participants with low thought 
disorder allocated to CBT, common for those with high thought disorder in the CBT group, 
and near certain for those allocated to supportive counselling regardless of thought disorder 
levels. The differences in the intercept attributable to thought disorder were of moderate 
size (R-square of 14.5%).  
 








4.1. Main findings 
Significant findings only emerged from the larger SOCRATES dataset. Delusional 
frequency appeared to reduce significantly more after 6 weeks in the CBT than supportive 
counselling group, with a slight but significant negative impact of thought disorder; but as 
frequency reduced towards eighteen months initial thought disorder predicted less 
improvement whatever the therapy (Figure 2). CBT produced significantly better, sustained 
reductions in distress from hallucinations than supportive counselling. Distress seemed 
worse after counselling even in those with greater thought disorder (Figure 3), who 
benefitted significantly less from CBT than those without. Although CBT did not predict 
significantly better 6-week outcomes or changes over follow-up than treatment as usual, 
the trends in its favour were consistent with the original trial report’s description of 
significant efficacy for therapy against total scores after 18 months (Tarrier et al. 2004).   
4.2. Strengths and limitations 
We have more trust in the relative differences found between treatments compared 
to the absolute differences found within treatments, because of the possibility that 
symptom measures and thought disorder ratings were endogenous (i.e. reflecting the same 
illness process). We tried to guard against this possibility by using different measures for 
symptoms (PSYRATS) and thought disorder (PANSS), the former being based on 
interpretation of self-ratings and the latter wholly observer-rated. Furthermore, the relative 
effects across treatments were protected by randomisation. This ensured that there would 
be no systematic differences in thought disorder, which was measured pre-randomisation, 
between the groups, and that this exogeneity across groups would also be carried over to 




The analysis used an unusually relaxed criterion for statistical significance because 
we wanted to have a lower than usual chance that we would miss potential evidence for the 
harmful effect of thought disorder on the efficacy of CBT for psychosis. Despite this, we 
found very little evidence for adverse effects of thought disorder; essentially no evidence for 
delusions and only limited evidence for hallucinations, where higher levels of thought 
disorder was associated with higher probability of hallucination within the CBT group. This 
was despite the fact that our study had the statistical power to detect reasonably small 
differences using the SOCRATES data (R-square of 4.2%). The smaller sample size of the 
ACTION data meant that our analysis would have been able to detect only larger differences 
(R-square > 15%). Considering the differential effects of thought disorder across treatments, 
we found no strong evidence that thought disorder is more problematic for CBT than for 
treatment as usual or supportive counselling. 
Although we found essentially the same pattern of results when using the different 
modelling approaches in the SOCRATES data, the differences attributable to the effects of 
thought disorder in the ACTION data were highly sensitive to the choice of using GSEM or 
GMLM. We believe this was most likely due to the much smaller sample size of the ACTION 
study compared to the SOCRATES study and the effect of this on the slightly different 
modelling assumptions and estimation methods. 
We used a measure of thought disorder derived from items on the PANSS, rather 
than a dedicated and validated measure of thought disorder. Thought disorder is a 
multifaceted construct (Andreasen, 1979) and is it likely that different subtypes could 
differentially influence the effectiveness of CBT, as well as in those with more severe 
thought disorder than found in our sample.   
The delivery of therapy in SOCRATES was relatively atypical in that it was front-
heavy; patients received the majority of sessions at the start of the intervention. A limitation 
of the current analysis was that it was restricted to two datasets that were available to the 
authors, which may not have been representative of randomised controlled trials more 
generally. In the future, it will be important to evaluate the impact of thought disorder on 
CBT in other datasets, including a purpose-designed trial replicating how therapy could be 




specifically target thought disorder, rather than focusing primarily on hallucinations and 
delusions (Palmier-Claus et al., 2017).  
  
4.3. Conclusion 
To the best of our knowledge, there is little research exploring the impact of thought 
disorder on the effectiveness of CBT for delusions and distress from hallucinations. Our 
results are novel in that they provide tentative evidence that CBT is not harmful for patients 
experiencing thought disorder. The UK’s NICE’s guidelines suggest that clinicians offer CBT 
to all patients with psychosis as a first line treatment. We found no compelling evidence to 
suggest that NICE should revise these recommendations to exclude patients experiencing 
thought disorder; CBT was significantly more successful than counselling in reducing 
delusional frequency in the short term and hallucinatory distress at any point, even in those 
with relatively high thought disorder.  Nevertheless, these findings underscore the 
importance of effective initial treatment of thought disorder in maximising the benefit of 
CBT for psychosis, particularly for reducing distress from hallucinations.  
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